Heparin in acute myocardial infarction

Area of Science:

• Cardiology
• Pharmacology

Background:

• Thrombolytic therapy is standard for acute myocardial infarction (AMI), but optimal patient aftercare remains unclear.
• Previous meta-analyses suggest heparin reduces mortality, reinfarction, and stroke in AMI patients.
• Recent studies investigate heparin's role within modern thrombolytic strategies.

Purpose of the Study:

• To evaluate the clinical effects of subcutaneous heparin in patients undergoing thrombolytic therapy for AMI.
• To assess heparin's impact on mortality, ischemic events, recurrent infarction, and ventricular thrombi.
• To compare heparin's efficacy with and without concomitant aspirin use.

Main Methods:

• Meta-analysis of twenty trials (pre-thrombolysis era) examining intravenous or subcutaneous heparin.
• Analysis of the SCATI study evaluating subcutaneous heparin (12,500 U BID) alongside thrombolysis.
• Review of GISSI 2 and International trials randomizing subcutaneous heparin with aspirin recommendations.

Main Results:

• Heparin significantly reduced mortality, reinfarction, and stroke in earlier trials.
• The SCATI study showed lower in-hospital mortality and reduced ventricular thrombi with heparin.
• No significant differences in mortality or recurrent infarction were observed with heparin in GISSI 2; however, embolic events decreased.

Conclusions:

• Subcutaneous heparin demonstrates benefits in managing acute myocardial infarction.
• Combining heparin with aspirin does not appear to provide consistent additional advantages.
• Heparin effectively prevents thrombus formation and embolic complications, effects not replicated by aspirin.